Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) - Total Assets
Based on the latest financial reports, Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) holds total assets worth CN¥2.07 Billion CNY (≈ $303.41 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Zhuhai Rundu Pharmaceutical Co Ltd Class debt service capacity to assess how comfortably operating cash covers total debt obligations.
Zhuhai Rundu Pharmaceutical Co Ltd Class A - Total Assets Trend (2011–2024)
This chart illustrates how Zhuhai Rundu Pharmaceutical Co Ltd Class A's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Zhuhai Rundu Pharmaceutical Co Ltd Class for net asset value and shareholders' equity analysis.
Zhuhai Rundu Pharmaceutical Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhuhai Rundu Pharmaceutical Co Ltd Class A's total assets of CN¥2.07 Billion consist of 40.4% current assets and 59.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.4% |
| Accounts Receivable | CN¥218.34 Million | 10.0% |
| Inventory | CN¥442.01 Million | 20.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥64.42 Million | 2.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Zhuhai Rundu Pharmaceutical Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Zhuhai Rundu Pharmaceutical Co Ltd Class.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhuhai Rundu Pharmaceutical Co Ltd Class A's current assets represent 40.4% of total assets in 2024, a decrease from 60.4% in 2011.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, down from 25.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 11.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 20.2% of total assets.
Zhuhai Rundu Pharmaceutical Co Ltd Class A Competitors by Total Assets
Key competitors of Zhuhai Rundu Pharmaceutical Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Zhuhai Rundu Pharmaceutical Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.60 | 1.90 | 2.16 |
| Quick Ratio | 0.85 | 0.88 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥325.78 Million | CN¥396.67 Million | CN¥417.01 Million |
Zhuhai Rundu Pharmaceutical Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Zhuhai Rundu Pharmaceutical Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.99 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | CN¥2.19 Billion |
| Market Capitalization | $533.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhuhai Rundu Pharmaceutical Co Ltd Class A's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhuhai Rundu Pharmaceutical Co Ltd Class A's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhuhai Rundu Pharmaceutical Co Ltd Class A (2011–2024)
The table below shows the annual total assets of Zhuhai Rundu Pharmaceutical Co Ltd Class A from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.19 Billion ≈ $321.00 Million |
-1.53% |
| 2023-12-31 | CN¥2.23 Billion ≈ $325.99 Million |
-2.56% |
| 2022-12-31 | CN¥2.29 Billion ≈ $334.56 Million |
+19.74% |
| 2021-12-31 | CN¥1.91 Billion ≈ $279.41 Million |
+26.14% |
| 2020-12-31 | CN¥1.51 Billion ≈ $221.51 Million |
+14.10% |
| 2019-12-31 | CN¥1.33 Billion ≈ $194.14 Million |
+16.54% |
| 2018-12-31 | CN¥1.14 Billion ≈ $166.59 Million |
+61.25% |
| 2017-12-31 | CN¥706.00 Million ≈ $103.31 Million |
+14.50% |
| 2016-12-31 | CN¥616.60 Million ≈ $90.23 Million |
+23.39% |
| 2015-12-31 | CN¥499.72 Million ≈ $73.12 Million |
+33.11% |
| 2014-12-31 | CN¥375.41 Million ≈ $54.93 Million |
+8.96% |
| 2013-12-31 | CN¥344.54 Million ≈ $50.42 Million |
+17.17% |
| 2012-12-31 | CN¥294.06 Million ≈ $43.03 Million |
+23.23% |
| 2011-12-31 | CN¥238.62 Million ≈ $34.92 Million |
-- |
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the process development, qu… Read more